Following FDA Review, Pharmaxis to Accelerate Plans for PXS-5505 Combination Study with JAK Inhibitor in Myelofibrosis Patients

12th Apr 23

Release Date: 12/04/2023 9:10am

  • FDA Provides Feedback after Review of Interim Safety and Efficacy Data from Ongoing Monotherapy Trial MF-101
  • Pharmaxis Plans to Commence Trial of Combination Therapy with Myelofibrosis Standard of Care Treatment in CY 2023

Read full media release - pdf

Categories: News and Media